Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-06-17 16:12:35 ET · period of report 2026-06-15 · accession 0000875320-26-000235 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-17 16:12 | 2026-06-15 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -4,062 | 17.0K | -19% | -$1.83M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-15 | S | D | 4,062 | $450.00 | 16,953 | D | — | — | (F1) Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. |